Articles From: Elie Tahari Seeks ChannelAdvisor’s Expertise for Optimal Marketplace Management to Elizabeth Arden, Inc. Announces Fourth Quarter and Fiscal 2013 Results


ChannelAdvisor (NYSE:ECOM) , a leading provider of cloud-based e-commerce solutions that enable retailers and manufactures to increase global sales, today announced that designer Elie Tahari will employ ChannelAdvisor’s Marketplaces solution and Managed Services team to maximize results on eBay and other marketplaces.
Sign-up for Elie Tahari Seeks ChannelAdvisor’s Expertise for Optimal Marketplace Management investment picks
2014/3/27
Kohl’s Department Stores (NYSE: KSS) today announced Elie Tahari will design the retailer’s fifth DesigNation limited-edition collection.
Sign-up for Elie Tahari to Partner with Kohl’s for Next DesigNation Collection investment picks
2013/8/22
FOX News Channel’s (FNC) Elisabeth Hasselbeck will debut as co-host of top-rated cable news morning show FOX & Friends (6:00-9:00 AM/ET) on Monday, September 16 th , announced Bill Shine, Executive Vice President of Programming for FOX News.
Sign-up for Elisabeth Hasselbeck to Debut as Co-Host of FOX & Friends on Monday, September 16th investment picks
2013/8/20
BEIJING , Aug.
Sign-up for Elite Global Hackers Come Together at SyScan360 in Beijing investment picks
NORTHVALE, N.J., Oct.
Sign-up for Elite Pharmaceuticals Announces Bridge Loan Facility investment picks
NORTHVALE, N.J., Nov.
Sign-up for Elite Pharmaceuticals Announces Conversion of Treppel Bridge Loan to Convertible Note investment picks
2013/10/8
NORTHVALE, N.J., Oct.
Sign-up for Elite Pharmaceuticals Announces Manufacturing and License Agreement for Twelve Generic Products investment picks
2014/3/24
NORTHVALE, N.J., March 24, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that on March 21, 2014, the Company filed a Changes Being Effected in 30 Days (CBE-30) supplemental application with the U.S. Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to Elite's Northvale facility.
Sign-up for Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine investment picks
2014/3/27
NORTHVALE, N.J., March 27, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that it has created the position of Vice President, Quality Operations & Regulatory Affairs and has hired industry veteran, Barbara Ellison, to fill that role.
Sign-up for Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs investment picks
2014/3/10
NORTHVALE, N.J., March 10, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding the Company's abuse deterrent technology with the issuance of Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance expands the scope and reach of Elite's patent estate internationally.
Sign-up for Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally investment picks
2013/12/5
NORTHVALE, N.J., Dec.
Sign-up for Elite Pharmaceuticals Initiates Pilot Bioequivalence Study for ELI-201 investment picks
2014/1/14
NORTHVALE, N.J., Jan.
Sign-up for Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Second Opioid Abuse Deterrent Product investment picks
2014/2/18
NORTHVALE, N.J., Feb.
Sign-up for Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201 investment picks
2014/3/5
NORTHVALE, N.J., March 5, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated in January 2014 for Elite's undisclosed abuse deterrent opioid product, ELI-200.
Sign-up for Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200 investment picks
2013/9/18
NORTHVALE, N.J., Sept.
Sign-up for Elite Pharmaceuticals, Inc. Announces First Shipment of Generic Naltrexone Hydrochloride investment picks
2013/8/13
NORTHVALE, N.J., Aug.
Sign-up for Elite Pharmaceuticals, Inc. Announces Fiscal Year 2014 First Quarter Conference Call on Thursday, August 15, 2013 investment picks
Elite Adds Twelve Approved Products to Its Pipeline NORTHVALE, N.J., Aug.
Sign-up for Elite Pharmaceuticals, Inc. Appoints Nasrat Hakim as President and Chief Executive Officer investment picks
2013/8/12
NORTHVALE, N.J., Aug.
Sign-up for Elite Pharmaceuticals, Inc. Hires Industry Veteran Doug Plassche as Executive Vice President of Operations investment picks
2013/8/14
NORTHVALE, N.J., Aug.
Sign-up for Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2014 investment picks
Revenues Increase by 83%, Product Development Accelerating Conference Call Scheduled for Monday, November 18 at 3:00 PM ET NORTHVALE, N.J., Nov.
Sign-up for Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2014 investment picks
2014/2/14
Revenues Increase by 154%, Product Development Accelerating NORTHVALE, N.J., Feb.
Sign-up for Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2014 investment picks
2013/11/14
NORTHVALE, N.J., Nov.
Sign-up for Elite Pharmaceuticals, Inc. to Host Second Quarter Business Update Call on November 18, 2013 investment picks
2014/2/10
NORTHVALE, N.J., Feb.
Sign-up for Elite Pharmaceuticals, Inc. to Host Third Quarter Business Update Call on February 18, 2014 investment picks
2014/1/30
By Erin McCarthy Elizabeth Arden Inc. (RDEN) has named former Proctor & Gamble executive Rod R.
Sign-up for Elizabeth Arden Appoints Proctor & Gamble's Little as Finance Chief investment picks
2014/3/24
Elizabeth Arden, Inc. (NASDAQ:RDEN), a global prestige beauty products company, introduces new Elizabeth Arden Rx , a comprehensive professional skincare line developed exclusively for physician offices.
Sign-up for Elizabeth Arden Introduces Elizabeth Arden Rx investment picks
2014/3/6
Elizabeth Arden, Inc. (NASDAQ:RDEN), a global prestige beauty products company, announces the launch of its new Elizabeth Arden Rx skincare line, which will be available exclusively in physician offices.
Sign-up for Elizabeth Arden Unveils Next Step in Multi-Channel Distribution Strategy investment picks
2014/1/30
Elizabeth Arden, Inc. (NASDAQ:RDEN), a global prestige beauty products company, announced today the appointment of Rod R.
Sign-up for Elizabeth Arden, Inc. Announces Appointment of Former P&G Executive as Chief Financial Officer investment picks
Elizabeth Arden, Inc. (NASDAQ:RDEN), a global prestige beauty products company, today announced financial results for its first fiscal quarter ended September 30, 2013.
Sign-up for Elizabeth Arden, Inc. Announces First Quarter Fiscal 2014 Results investment picks
Elizabeth Arden, Inc. (NASDAQ: RDEN) , a global prestige beauty products company, today announced financial results for its fourth fiscal quarter and fiscal year ended June 30, 2013.
Sign-up for Elizabeth Arden, Inc. Announces Fourth Quarter and Fiscal 2013 Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Elie Tahari Seeks ChannelAdvisor’s Expertise for Optimal Marketplace Management to Elizabeth Arden, Inc. Announces Fourth Quarter and Fiscal 2013 Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity